Soligenix
About
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.50M
- Industries
- Biopharma,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 1987
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Soligenix is a late-stage research and development biopharmaceutical company that focuses on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early-stage development to advanced development and manufacturing.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 28, 2020 | Grant | $1.50M | 1 |
National Institutes of Health
|
— | Detail |
| Sep 18, 2017 | Grant | $1.50M | 1 |
National Institutes of Health
|
— | Detail |
| Jul 2, 2010 | Series Unknown | $5.90M | 3 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Rockmore Capital
|
— | Series Unknown |
Downsview Capital
|
— | Series Unknown |
Brio Capital Management
|
— | Series Unknown |
